Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Revenue of Collegium Pharmaceutical, Inc. (COLL)
Revenue in 2023 (TTM): $566.77 M
According to Collegium Pharmaceutical, Inc.'s latest financial reports the company's current revenue (TTM) is $566.77 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Collegium Pharmaceutical, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $566.77 M | $326.17 M | $308.33 M | $75.73 M | $48.16 M |
| 2022 | $463.93 M | $209.49 M | $168.76 M | $-28,847,000 | $-25,002,000 |
| 2021 | $276.87 M | $150.62 M | $86.58 M | $-3,374,000 | $71.52 M |
| 2020 | $310.02 M | $179.84 M | $118.07 M | $27.58 M | $26.75 M |
| 2019 | $296.7 M | $103.04 M | $-6,017,000 | $-22,722,000 | $-8,148,000 |
| 2018 | $280.41 M | $114.74 M | $91.91 M | $-39,128,000 | $-39,128,000 |
| 2017 | $28.48 M | $25.88 M | $-74,271,000 | $-74,865,000 | $-74,865,000 |
| 2016 | $1.71 M | $1.5 M | $-93,427,000 | $-94,176,000 | $-94,176,000 |
| 2015 | $ | $-171,000 | $-26,645,000 | $-27,255,000 | $-27,255,000 |
| 2014 | $ | $ | $-17,478,000 | $-17,917,000 | $-17,917,000 |
| 2013 | $ | $ | $-15,952,000 | $-16,197,000 | $-16,197,000 |